• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群与心血管疾病:揭示生态失调和微生物代谢产物的作用

Gut Microbiota and Cardiovascular Diseases: Unraveling the Role of Dysbiosis and Microbial Metabolites.

作者信息

Muttiah Barathan, Hanafiah Alfizah

机构信息

Department of Medical Microbiology and Immunology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.

GUT Research Group, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia.

出版信息

Int J Mol Sci. 2025 Apr 30;26(9):4264. doi: 10.3390/ijms26094264.

DOI:10.3390/ijms26094264
PMID:40362500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12072866/
Abstract

Cardiovascular diseases (CVDs), including heart failure (HF), hypertension, myocardial infarction (MI), and atherosclerosis, are increasingly linked to gut microbiota dysbiosis and its metabolic byproducts. HF, affecting over 64 million individuals globally, is associated with systemic inflammation and gut barrier dysfunction, exacerbating disease progression. Similarly, hypertension and MI correlate with reduced microbial diversity and an abundance of pro-inflammatory bacteria, contributing to vascular inflammation and increased cardiovascular risk. Atherosclerosis is also influenced by gut dysbiosis, with key microbial metabolites such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs) playing crucial roles in disease pathogenesis. Emerging evidence highlights the therapeutic potential of natural compounds, including flavonoids, omega-3 fatty acids, resveratrol, curcumin, and marine-derived bioactives, which modulate the gut microbiota and confer cardioprotective effects. These insights underscore the gut microbiota as a critical regulator of cardiovascular health, suggesting that targeting dysbiosis may offer novel preventive and therapeutic strategies. Further research is needed to elucidate underlying mechanisms and optimize microbiome-based interventions for improved cardiovascular outcomes.

摘要

心血管疾病(CVDs),包括心力衰竭(HF)、高血压、心肌梗死(MI)和动脉粥样硬化,越来越多地与肠道微生物群失调及其代谢副产物相关联。心力衰竭在全球影响着超过6400万人,与全身炎症和肠道屏障功能障碍有关,会加剧疾病进展。同样,高血压和心肌梗死与微生物多样性降低和促炎细菌大量存在相关,会导致血管炎症并增加心血管疾病风险。动脉粥样硬化也受肠道微生物群失调影响,关键的微生物代谢产物如氧化三甲胺(TMAO)和短链脂肪酸(SCFAs)在疾病发病机制中起关键作用。新出现的证据凸显了天然化合物的治疗潜力,包括类黄酮、ω-3脂肪酸、白藜芦醇、姜黄素和海洋来源的生物活性物质,它们可调节肠道微生物群并赋予心脏保护作用。这些见解强调肠道微生物群是心血管健康的关键调节因子,表明针对微生物群失调可能提供新的预防和治疗策略。需要进一步研究以阐明潜在机制并优化基于微生物群的干预措施,以改善心血管疾病结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/7ec42c5a22cc/ijms-26-04264-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/3b7aac04bede/ijms-26-04264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/5b999fc7c4a5/ijms-26-04264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/7ec42c5a22cc/ijms-26-04264-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/3b7aac04bede/ijms-26-04264-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/5b999fc7c4a5/ijms-26-04264-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526a/12072866/7ec42c5a22cc/ijms-26-04264-g003.jpg

相似文献

1
Gut Microbiota and Cardiovascular Diseases: Unraveling the Role of Dysbiosis and Microbial Metabolites.肠道微生物群与心血管疾病:揭示生态失调和微生物代谢产物的作用
Int J Mol Sci. 2025 Apr 30;26(9):4264. doi: 10.3390/ijms26094264.
2
Antibiotic-induced gut dysbiosis: unraveling the gut-heart axis and its impact on cardiovascular health.抗生素诱导的肠道菌群失调:揭示肠道-心脏轴及其对心血管健康的影响。
Mol Biol Rep. 2025 Mar 17;52(1):319. doi: 10.1007/s11033-025-10425-2.
3
The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Implications.肠道微生物群及其相关化合物在心血管健康中的作用及其治疗意义。
Cardiovasc Hematol Agents Med Chem. 2024;22(3):375-389. doi: 10.2174/0118715257273506231208045308.
4
Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.肠道微生物群及其代谢物对慢性肾脏病心血管并发症的贡献作用。
Semin Nephrol. 2018 Mar;38(2):193-205. doi: 10.1016/j.semnephrol.2018.01.008.
5
Interaction between gut microbiome and cardiovascular disease.肠道微生物组与心血管疾病的相互作用。
Life Sci. 2018 Dec 1;214:153-157. doi: 10.1016/j.lfs.2018.10.063. Epub 2018 Oct 29.
6
Gut microbiota and microbiota-derived metabolites in cardiovascular diseases.心血管疾病中的肠道微生物群和微生物衍生代谢产物
Chin Med J (Engl). 2023 Oct 5;136(19):2269-2284. doi: 10.1097/CM9.0000000000002206.
7
Angiogenesis, a key point in the association of gut microbiota and its metabolites with disease.血管生成是肠道微生物群及其代谢产物与疾病关联中的一个关键点。
Eur J Med Res. 2024 Dec 23;29(1):614. doi: 10.1186/s40001-024-02224-5.
8
The Gut-Heart Axis: Molecular Perspectives and Implications for Myocardial Infarction.肠-心轴:分子视角与心肌梗死的意义。
Int J Mol Sci. 2024 Nov 20;25(22):12465. doi: 10.3390/ijms252212465.
9
The gut microbiota as a novel regulator of cardiovascular function and disease.肠道微生物群作为心血管功能和疾病的新型调节因子。
J Nutr Biochem. 2018 Jun;56:1-15. doi: 10.1016/j.jnutbio.2017.12.010. Epub 2017 Dec 27.
10
Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review.解析微生物组在神经源性高血压中的作用的机制见解:全面综述。
Pathol Res Pract. 2023 Sep;249:154740. doi: 10.1016/j.prp.2023.154740. Epub 2023 Aug 6.

引用本文的文献

1
The Association of SARS-CoV-2 Infection and COVID-19 Vaccination With Sudden Death: An Explorative Review.严重急性呼吸综合征冠状病毒2感染及2019冠状病毒病疫苗接种与猝死的关联:一项探索性综述
Cureus. 2025 Aug 7;17(8):e89527. doi: 10.7759/cureus.89527. eCollection 2025 Aug.
2
Prognostic value of gut microbiota and low-density lipoprotein cholesterol subfractions in patients with ST-segment elevation myocardial infarction.ST段抬高型心肌梗死患者肠道微生物群和低密度脂蛋白胆固醇亚组分的预后价值
Front Immunol. 2025 Aug 13;16:1610001. doi: 10.3389/fimmu.2025.1610001. eCollection 2025.
3
Gut microbiota regulate atherosclerosis via the gut-vascular axis: a scoping review of mechanisms and therapeutic interventions.

本文引用的文献

1
Trimethylamine-N-Oxide (TMAO) as a Rising-Star Metabolite: Implications for Human Health.氧化三甲胺(TMAO)作为一种后起之秀的代谢物:对人类健康的影响
Metabolites. 2025 Mar 24;15(4):220. doi: 10.3390/metabo15040220.
2
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy.肠道微生物群失调:发病机制、疾病、预防与治疗
MedComm (2020). 2025 Apr 18;6(5):e70168. doi: 10.1002/mco2.70168. eCollection 2025 May.
3
Dietary Phytochemicals in Health and Disease: Mechanisms, Clinical Evidence, and Applications-A Comprehensive Review.
肠道微生物群通过肠-血管轴调节动脉粥样硬化:机制与治疗干预的范围综述
Front Microbiol. 2025 Aug 8;16:1606309. doi: 10.3389/fmicb.2025.1606309. eCollection 2025.
4
Unlocking the Secrets of Nature: Phytochemicals as Key Players in Longevity and Healthy Aging.揭开自然的秘密:植物化学物质是长寿和健康衰老的关键因素。
Cell Biochem Biophys. 2025 Aug 22. doi: 10.1007/s12013-025-01872-6.
5
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.针对代谢紊乱的肠道微生物群靶向疗法:对益生菌发酵草药生物活性成分协同作用的机制洞察
Int J Mol Sci. 2025 Jun 7;26(12):5486. doi: 10.3390/ijms26125486.
饮食中的植物化学物质与健康和疾病:作用机制、临床证据及应用——全面综述
Food Sci Nutr. 2025 Mar 19;13(3):e70101. doi: 10.1002/fsn3.70101. eCollection 2025 Mar.
4
A review of gut failure as a cause and consequence of critical illness.作为危重病病因及后果的肠衰竭综述。
Crit Care. 2025 Feb 26;29(1):91. doi: 10.1186/s13054-025-05309-7.
5
Flavonoids as Natural Anti-Inflammatory Agents in the Atopic Dermatitis Treatment.黄酮类化合物作为特应性皮炎治疗中的天然抗炎剂
Pharmaceutics. 2025 Feb 15;17(2):261. doi: 10.3390/pharmaceutics17020261.
6
Antioxidant and Anti-Inflammatory Effects of Bioactive Compounds in Atherosclerosis.生物活性化合物在动脉粥样硬化中的抗氧化和抗炎作用
Int J Mol Sci. 2025 Feb 6;26(3):1379. doi: 10.3390/ijms26031379.
7
Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease.益生菌:预防和管理心血管疾病的潜在策略。
Nutrients. 2024 Dec 27;17(1):52. doi: 10.3390/nu17010052.
8
Regulation of bile acids and their receptor FXR in metabolic diseases.胆汁酸及其受体FXR在代谢性疾病中的调控
Front Nutr. 2024 Dec 11;11:1447878. doi: 10.3389/fnut.2024.1447878. eCollection 2024.
9
Microplastics and human health: unveiling the gut microbiome disruption and chronic disease risks.微塑料与人类健康:揭示肠道微生物群紊乱及慢性病风险
Front Cell Infect Microbiol. 2024 Nov 25;14:1492759. doi: 10.3389/fcimb.2024.1492759. eCollection 2024.
10
Efficacy of Different Beta Blockers in Reducing Mortality in Heart-Failure Patients.不同β受体阻滞剂对降低心力衰竭患者死亡率的疗效
Cureus. 2024 Nov 21;16(11):e74171. doi: 10.7759/cureus.74171. eCollection 2024 Nov.